The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Case Report

Epidermodysplasia Verruciformis

Authors: Joshua E. Lane, MD, Paul H. Bowman, MD, David J. Cohen, MD

Abstract

Epidermodysplasia verruciformis is an uncommon cutaneous entity characterized by persistent human papillomavirus infection. A defect in cell-mediated immunity is the suggested causative factor. Numerous specific human papillomavirus types have been detected in this disease. Multiple nonmelanoma skin cancers are commonly seen in such patients; thus, early diagnosis is beneficial.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Lewandowsky F, Lutz W. Ein Fall einer bisher nicht beschriebenen Hauterkrankung (Epidermodysplasia verruciformis). Arch Dermatol Syphilol 1922; 141: 193–203.
2. Jacyk WK, deVilliers EM. Epidermodysplasia verruciformis in Africans. Int J Dermatol 1993; 32: 806–810.
3. Jablonska S, Majewski S. Epidermodysplasia verruciformis: Immunological and clinical aspects. Curr Top Microbiol Immunol 1994; 186: 157–175.
4. Lutzner MA. Epidermodysplasia verruciformis: An autosomal recessive disease characterized by viral warts and skin cancer. Bull Cancer 1978; 65: 169–182.
5. Harris AJ, Purdie K, Leigh IM, Proby C, Burge S. A novel human papillomavirus identified in epidermodysplasia verruciformis. Br J Dermatol 1997; 136: 587–591.
6. Majewski S, Skopinska-Rozewska E, Jablonska S, Wasik M, Misiewicz J, Orth G. Partial defects of cell-mediated immunity in patients with epidermodysplasia verruciformis. J Am Acad Dermatol 1986; 15: 966–973.
7. Cooper KD, Androphy EJ, Lowy DR, Katz SI. Antigen presentation and T-cell activation in epidermodysplasia verruciformis. J Invest Dermatol 1990; 94: 769–776.
8. Haftek M, Jablonska S, Szmanczyk J, Jarzabek-Chorzelska M. Langerhans cells in epidermodysplasia verruciformis. Dermatologica 1987; 174: 173–179.
9. Yutsudo M, Hakura A. Human papillomavirus type 17 transcripts expressed in skin carcinoma tissue of a patient with epidermodysplasia verruciformis. Int J Cancer 1987; 39: 586–589.
10. Deau MC, Favre M, Orth G. Genetic heterogeneity among human papillomaviruses (HPV) associated with epidermodysplasia verruciformis: Evidence for multiple allelic forms of HPV5 and HPV8 E6 genes. Virology 1991; 184: 492–503.
11. Astori G, Lavergne D, Benton C, Hockmayr B, Egawa K, Garbe C, et al. Human papillomaviruses are commonly found in normal skin of immunocompetent hosts. J Invest Dermatol 1998; 110: 752–755.
12. Steger G, Olsewsky M, Stockfleth E, Pfister H. Prevalence of antibodies to human papilloma virus type in the human sera. J Virol 1990; 64: 4399–4406.
13. Androphy EJ, Dvoretsky I, Lowy DR. X-linked inheritance of epidermodysplasia verruciformis: Genetic and virologic studies of a kindred. Arch Dermatol 1985; 121: 864–868.
14. Karrer S, Szeimies RM, Abels C, Wlotzke U, Stolz W, Landthaler M. Epidermodysplasia verruciformis treated using topical 5-aminoaevulinic acid photodynamic therapy. Br J Dermatol 1999; 140: 935–938.

Only when we learn to see the invisible, Will we learn to do the impossible. —Frank Gaines